MML Investors Services LLC Boosts Stock Holdings in GlaxoSmithKline plc (NYSE:GSK)

Share on StockTwits

MML Investors Services LLC raised its holdings in shares of GlaxoSmithKline plc (NYSE:GSK) by 1.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 123,308 shares of the pharmaceutical company’s stock after buying an additional 1,815 shares during the period. MML Investors Services LLC’s holdings in GlaxoSmithKline were worth $4,935,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Renaissance Technologies LLC boosted its position in GlaxoSmithKline by 6.9% during the second quarter. Renaissance Technologies LLC now owns 15,261,781 shares of the pharmaceutical company’s stock valued at $610,776,000 after buying an additional 989,181 shares during the period. Equity Investment Corp boosted its position in GlaxoSmithKline by 3.9% during the first quarter. Equity Investment Corp now owns 2,776,791 shares of the pharmaceutical company’s stock valued at $116,042,000 after buying an additional 105,044 shares during the period. Parametric Portfolio Associates LLC boosted its position in GlaxoSmithKline by 4.1% during the first quarter. Parametric Portfolio Associates LLC now owns 2,765,250 shares of the pharmaceutical company’s stock valued at $115,560,000 after buying an additional 107,713 shares during the period. Brandes Investment Partners LP boosted its position in GlaxoSmithKline by 2.1% during the first quarter. Brandes Investment Partners LP now owns 2,085,398 shares of the pharmaceutical company’s stock valued at $87,149,000 after buying an additional 42,656 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in GlaxoSmithKline by 5.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,769,859 shares of the pharmaceutical company’s stock valued at $67,626,000 after buying an additional 88,148 shares during the period. Institutional investors and hedge funds own 11.16% of the company’s stock.

In related news, Director Plc Glaxosmithkline purchased 177,777 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The stock was bought at an average cost of $45.00 per share, with a total value of $7,999,965.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 10.00% of the company’s stock.

A number of research firms have recently weighed in on GSK. Morgan Stanley reiterated an “underweight” rating on shares of GlaxoSmithKline in a report on Monday, June 17th. Jefferies Financial Group reiterated a “buy” rating on shares of GlaxoSmithKline in a report on Thursday, August 29th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a report on Tuesday, August 13th. Cowen reiterated a “hold” rating and set a $45.00 target price on shares of GlaxoSmithKline in a report on Monday, June 10th. Finally, ValuEngine lowered shares of GlaxoSmithKline from a “hold” rating to a “sell” rating in a report on Tuesday. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and three have assigned a buy rating to the stock. GlaxoSmithKline presently has a consensus rating of “Hold” and an average target price of $41.79.

Shares of GlaxoSmithKline stock traded down $0.14 during trading on Friday, reaching $40.89. 76,720 shares of the stock were exchanged, compared to its average volume of 2,031,593. The company has a quick ratio of 0.48, a current ratio of 0.71 and a debt-to-equity ratio of 7.86. The stock’s fifty day moving average is $41.15 and its 200 day moving average is $40.58. The firm has a market cap of $102.21 billion, a price-to-earnings ratio of 12.93, a price-to-earnings-growth ratio of 1.96 and a beta of 0.70. GlaxoSmithKline plc has a 1 year low of $36.41 and a 1 year high of $42.49.

GlaxoSmithKline (NYSE:GSK) last posted its earnings results on Wednesday, July 24th. The pharmaceutical company reported $0.78 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.64 by $0.14. The company had revenue of $10.04 billion during the quarter, compared to analyst estimates of $9.55 billion. GlaxoSmithKline had a net margin of 13.84% and a return on equity of 175.45%. Equities analysts forecast that GlaxoSmithKline plc will post 2.96 earnings per share for the current year.

GlaxoSmithKline Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Read More: Backdoor Roth IRA

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.